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[57] ABSTRACT 
Transgenic mice express increased levels of neurotrophin-3 
(NT-3) in epithelium When their ancestors are microinjected 
With the NT-3 gene. The NT-3 groWth factor expressing 
transgenic mice are useful in the study of neurodegenerative 
disorders of the brain such as Parkinson’s syndrome and 
AlZheimer’s disease, of the spinal cord motor neurons such 
as amyotrophic lateral sclerosis, and for testing drug candi 
dates for the treatment of these diseases. 
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TRANSGENIC MICE WHICH 
OVEREXPRESS NEUROTROPHIN-3 (NT-3) 
AND METHODS OF USE 
TECHNICAL FIELD 
The present invention relates to transgenic mice that 
express increased levels of neurotrophin 3 (NT-3) in the 
epidermis and other strati?ed, keratiniZed epithelium. The 
transgenic mice have an altered peripheral nervous system 
shoWing rescued NT-3 responsive neurons from a pro 
grammed cell death that normally occurs in development. 
This is evidenced by an increase in the number of trk C 
receptor expressing sensory neurons in the phenotype of the 
transgenic mouse. In addition, K14-NT-3 mice have larger 
Merkel cell (touch dome) sensory units in the skin than 
controls. The NT-3 expressing transgenic mice of the present 
invention are valuable to researchers that study the role of 
NT-3 in the development and function of the central nervous 
system and peripheral nervous system. 
BACKGROUND ART 
Neurotrophin proteins support survival and differentiation 
of developing neurons. Target tissues such as skin produce 
limited amounts of neurotrophins during critical periods of 
development that act to rescue neurons from programmed 
cell death. Though target-derived in?uences of nerve groWth 
factor (NGF) have been Well documented, effects of other 
neurotrophins are less clear. 
During development of the vertebrate nervous system up 
to half of all neurons generated undergo a process of 
naturally occurring cell death (See Ard, M. D., Morest, 
D. K. (1984),; Intl. J. Dev. Neurosci. 2, 535—547; and 
Oppenheim, R. W. (1991). Ann. Rev. Neurosci. 14, 
453—501). 
Neuronal death typically occurs shortly after neurons 
make functional connections Within their target ?eld. Sur 
vival during this period of innervation is thought to be 
dependent on the synthesis by the target tissue of a limited 
quantity of neurotropic substances. (See Thoenen, H. and 
Barde, Y. A. (1980), Physiol. Rev. 60, 1284—1334; 
Oppenheim, R. W. (1989), Trends in Neurosci. 12, 252—255; 
and Davies, A. M., Larmet, Y., Wright, E., Vogel, K. S. 
(1991), J. Cell Sci. 15, 111—116)). 
The competition for target ?eld-derived neurotrophic fac 
tors is thought to serve at least tWo functions: to ensure that 
an appropriate number of synaptic contacts are made at the 
target and to eliminate inappropriate neuronal projections. 
(See Oppenheim, R. W. (1981),. In Studies in Developmen 
tal Biology (ed. W. M. CoWan) p 74—133. Oxford University 
Press; and CoWan, W. M., FaWcett, J. W., O’Leary, D. D. M., 
and Stan?eld, B. B. (1984), Science 225, 1258—1265)). 
This concept is referred to as the neurotrophic hypothesis 
and predicts that the number of neurons in the adult could be 
increased if a higher concentration of neurotrophic factor(s) 
Was available during the critical time When synaptic contacts 
are being established. 
The NT-3 neurotrophin appears to have a role in neuron 
survival and maintenance. NT-3 is a member of the brain 
derived neurotrophic factor (BDNF)/nerve groWth factor 
(NGF) neurotrophin-4 (NT-4) gene family. The development 
and maintenance of the nervous system depends on these 
proteins knoWn as neurotrophic factors. Widespread neu 
ronal cell death accompanies normal development of the 
central nervous system and peripheral nervous system, and 
plays a crucial role in regulating the number of neurons 
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Which project to a given target ?eld (Berg, 1982, Neuronal 
Development, 397—331; CoWan et al., 1984, 225:1258—65). 
Ablation and transplantation studies of peripheral target 
tissues during development have shoWn that neuronal cell 
death results from the competition among neurons for lim 
iting amounts of survival factors (neurotrophic factors) 
produced in their projection ?elds. These observations led to 
the identi?cation of nerve groWth factor (NGF), Which 
remains by far the best characteriZed neurotrophic molecule 
(Levi, Montalchini, and Angeletti, 1968, Physiol. Rev., 
48:534—69; Thoenen and Barde, 1980, Rev. 60:1284—335). 
Because NGF supports only a limited set of neuronal 
populations, the existence of additional neurotrophic factors 
has long been postulated (Varon, S. and Adler, R., 1981, 
Adv. Cellular Neurobiology, 2: 115—63; Barde et al., 1987, 
Prob. Brain Res., 71:185—9). While it is noW clear that other 
neurotrophic factors exist, their extremely loW abundance 
has impeded their molecular characteriZation. Nevertheless, 
puri?cation of small amounts of tWo such proteins, namely 
brain derived neurotrophic factor and ciliary neurotrophic 
factor have recently permitted their cloning and sequencing 
(Leibrock et al., 1989, Nature, 341:149—52; Stockli et al., 
1989, Nature, 342:21—28; and Lin et al., 1989, Science, 
246:1023—25). 
There have been numerous reports of neurotrophic factor 
activity in extracts of a great variety of tissues and in 
conditioned culture media of many different cell types. 
Progress in characteriZing these activities and purifying the 
compounds has been hampered by the fact that such activi 
ties are present in extremely small amounts, the range of 
picograms and nanograms per gram of tissue. 
Nerve groWth factor (NGF) is a prototypical target 
derived neurotrophic substance that has been shoWn to be 
essential for the survival and differentiation of neural crest 
derived sensory neurons, sympathetic neurons, and fore 
brain cholinergic neurons. (See Levi-Montalcini, R. and 
Booker B. (1960), Proc. Natl. Acad. Sci. USA 46, 384—391, 
and Hefti, F. (1986) J. Neurosci. 6, 2155—2161; Williams, L. 
R., Varon, S., Peterson, G., Wictorin, K., Fischer, W., 
Bjorklund, A. & Gage, F. H. (1986), Proc. Natl. Acad. Sci. 
USA. 83, 9231—9235). 
US. Pat. No. 5,180,820 to Barde et al. discloses nucleic 
acid sequences encoding brain derived neurotrophic factor 
of humans. US. Pat. No. 5,229,500 to Barde et al. claims 
pharmaceutical compositions including puri?ed isolated 
nucleic acid sequences encoding brain derived neurotrophic 
factor. 
US. Pat. No. 5,169,764 to Shooter et al. discloses and 
claims a nucleic acid molecule encoding a chimeric protein 
Which has neurotrophic activity and consists of a chimeric 
protein including tWo neurotrophic factors selected from 
brain derived neurotrophic factor, ciliary neurotrophic 
factor, neurotrophin-3 and nerve groWth factor. 
US. Pat. No. 5,235,043 to Collins et al. discloses and 
claims a method for folding human mature nerve groWth 
factor recombinantly expressed in E. coli Wherein the pro 
tein maintains substantially full biological activity. US. Pat. 
No. 5,218,094 to de La Valle discloses a nominal neu 
rotrophic factor isolated from mammalian brain tissue. US. 
Pat. No. 5,349,056 to Panayotatos discloses and claims a 
modi?ed human ciliary neurotrophic factor. US. Pat. No. 
5,364,769 to Rosenthal et al. discloses neurotrophic factor-4, 
isolated nucleotide sequences. US. Pat. No. 5,210,026 to 
Kovesdi et al. discloses human MK protein Which is 
homologous to humor- and heparin-binding neurotrophic 
factor. 
5,859,311 
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US. Pat. No. 5,272,063 to Chan et al. discloses and 
claims a method of producing biologically active mature 
human [3-nerve growth factor in insect cells. 
International Publication WO 91/03568 to Hyman et al. 
discloses a derived neurotrophic factor and claims recom 
binant DNA molecule comprising a nucleic acid sequence 
encoding brain derived neurotrophic factor. 
International Publication 91/03569 to Hohn discloses 
neurotrophin-3. The publication claims a recombinant DNA 
molecule comprising a nucleic acid sequence encoding 
neurotrophin-3 or subsequences thereof. This international 
publication is incorporated herein by reference in its entirety. 
Various transgenic mice have been patented. US. Pat. No. 
4,736,866 to Leder et al. discloses a transgenic non-human 
eukaryotic animal Whose germ cells and somatic cells con 
tain an activated oncogene sequence introduced into the 
animal or an ancestor of the animal at an embryonic stage. 
The embryo of the mice Were microinjected With approxi 
mately 500 copies of the RSV-S107 c-myc plasmid. The 
injected eggs Were transferred to pseudopregnant foster 
mothers and alloWed to develop to term. The plasmid 
contains a Rous Sarcoma Virus enhancer and promoter 
sequence. The resultant mice shoWed expression of the 
c-myc gene in the salivary gland, spleen, testes, lung, brain, 
and preputial gland and intestinal tissue. 
US. Pat. No. 5,175,383 to Leder et al. discloses a male 
transgenic mouse containing germ cells and somatic cells 
Which contain a recombinant gene Which is a vertebrate gene 
in the Int-2/FGF family Which is capable of promoting 
benign prostatic hyperplasia or hypertrophy. The fusion gene 
Which is injected into the mouse embryonic tissue comprises 
a promoter sequence controlling transcription of the recom 
binant gene such as a promoter derived from the mouse 
mammary tumor virus and cytomegalovirus. The recombi 
nant gene is preferably substantially homologous With (i.e., 
greater than 50% homologous in terms of encoded amino 
acid sequence) a naturally occurring, vertebrate gene in the 
Int-2/FGF gene family of murine groWth factor encoding 
genes or their vertebrate counterparts, including the murine 
acidic or basic ?broblast groWth factor genes, the murine 
FGF-5 gene, the murine epidermal groWth factor gene, the 
murine insulin-like groWth factor-1 and -2 gene, the murine 
ot-transforming groWth factor gene With a murine hst/KS3 
gene. The transgenic mice of Leder et al. exhibit prostate 
hyperplasia and give sterile offspring. 
US. Pat. No. 5,087,571 to Leder et al. discloses a 
non-human eukaryotic animal Whose germ cells and somatic 
cells contain an activated oncogene. The embryo of the mice 
Were microinjected With approximately 500 copies of the 
RSV-S107 c-myc plasmid. The injected eggs Were trans 
ferred to pseudopregnant foster mothers and alloWed to 
develop to term. The plasmid contains a Rous Sarcoma Virus 
enhancer and promoter sequence. The resultant mice 
shoWed expression of the c-myc gene in the salivary gland, 
spleen, testes, lung, brain, and preputial gland and intestinal 
tissue. 
US. Pat. No. 5,175,384 to Krimpenfort et al. discloses 
transgenic mice having a phenotype characteriZed by the 
substantial absence of mature T-lymphocytes. The mouse is 
produced by introducing a transgene into a Zygote of a 
mouse Which comprises gene fragment Which encodes a 
T-cell antigen receptor polypeptide variant Which is inca 
pable of mediating T-cell maturation in the transgenic 
mouse. 
US. Pat. No. 5,175,385 to Wagner et al. discloses the 
production of a transgenic mouse With enhanced viral resis 
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tance Which is transmissible to its offspring. The transgenic 
mouse is prepared by introduction of a gene encoding a 
human interferon having anti-viral activity into a host 
mouse. The plasmid of Wagner et al. contains a 
methallothionein-1 promoter and the genomic human beta 
interferon gene. When these mice Were injected With pseu 
dorabies virus they shoWed an increased resistance to the 
virus and although many mice died they died considerably 
later than did the control animals. 
Vassar et al., in the Proceedings of the National Academy 
of Sciences, Volume 86, pages 1563—1567, March 1989, 
disclose “Tissue-speci?c and Differentiation-speci?c 
Expression of a Human K14 Keratin Gene in Transgenic 
Mice”. This publication discloses that Vassar et al. used a 
plasmid containing a K14 keratin promoter and a K14 
keratin gene sequence tagged With a sequence from the 
neuropeptide substance P and determined the expression of 
the plasmid and K14 keratin tagged substance P in the skin 
of transgenic mice. 
Vassar et al. in Gene & Development, Volume 5, pages 
714—727, (1991) disclose “Transgenic Mice Provide NeW 
Insights into the Role of TGF-ot During Epidermal Devel 
opment and Differentiation”. This publication discloses the 
construction of transgenic mice using a plasmid Which 
contains the K14 keratin promoter and the TGF-ot gene. 
Vassar et al. disclose that the TGF-ot gene belongs to the 
epidermal groWth factor family of proteins and shoWs struc 
tural homology With the epidermal groWth factor. These 
transgenic mice shoWed gross phenotypic abnormalities in 
their skin including ?aky outer epidermal layers With stunted 
hair groWth and Wrinkling. The plasmid used to create this 
transgenic mouse also included human groWth hormone 
fusion gene. 
US. Pat. No. 5,387,742 discloses transgenic mice Which 
exhibit amyloid brain deposits characteristic of AlZheimer’s 
disease. 
PCT Publication WO 93/00909 is directed to a method of 
treating neurotrophin-expressing tumors by administering a 
sequence complementary to at least a portion of a RNA 
transcript of brain-derived neurotrophic factor gene. 
Heretofore there has been no convenient method to inves 
tigate hoW neurotrophic factors such as NT-3, affect neuron 
survival and development of the peripheral nervous system 
or provide a practical model for testing drug candidates for 
the treatment of neurodegenerative disorders of the brain 
such as Parkinson’s syndrome and AlZheimer’s disease and 
assessing the effect of drug candidates on the central nervous 
system (CNS) and peripheral nervous system (PNS). 
The present invention overcomes the de?ciency by pro 
viding transgenic mice Which express increased levels of 
Neurotrophin-3 in the epidermis and other strati?ed, kera 
tiniZed epithelium. The transgene DNA construct injected 
into the mouse embryos contain a human K14 keratin 
promoter and enhancer region linked to the coding 
sequences of mouse Neurotrophin-3 gene. The mice can be 
used to study the role of NT-3 in supporting neuronal 
survival and in neurodegenerative disorders of the CNS and 
PNS. 
SUMMARY OF THE INVENTION 
The invention provides a transgenic mouse Whose somatic 
and germ cells contain and express a gene encoding for 
NT-3. The gene Was introduced into a mouse or an ancestor 
of the mouse at an embryonic stage. The NT-3 gene is 
operatively linked to a human K14 keratin promoter and 
enhancer region. The increased expression of the transgene 
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Was achieved by adding a region from the human growth 
hormone gene at the 3‘ end of the construct. The NT-3 in 
transgenic mice appears to alter the peripheral nervous 
system by rescuing NT-3 responsive neurons from a pro 
grammed cell death that normally occurs in development. 
NT-3 transgenic mice appear to have more nerve terminals 
in the skin, particularly in association With hairs and touch 
dome mechanoreceptor endings. 
The invention also provides for a mouse Wherein the NT-3 
gene has been introduced into an ancestor of said mouse at 
an embryonic stage by microinjection. In an additional 
embodiment, the mouse NT-3 gene is further operatively 
linked to the human groWth hormone gene. 
The invention provides for a mouse Which has a pheno 
type characteriZed by an altered peripheral nervous system 
shoWing rescued NT-3 responsive neurons from a pro 
grammed cell death that normally occurs in development. 
This is evidenced by an increase in the number of trk C 
receptor expressing sensory neurons in the phenotype of the 
transgenic mouse. In addition, K14-NT-3 mice have larger 
Merkel cell (touch dome) sensory units in the skin than 
controls. 
Advantageously, the present invention provides a method 
of producing the transgenic mouse Which overexpresses 
NT-3 Which comprises 
(a) providing a mouse NT-3 gene operatively linked to a 
human K14 keratin promoter and enhancer region 
functional in said mouse; 
(b) introducing said gene into a mouse embryo; 
(c) transplanting said embryo into a pseudopregnant 
mouse; and 
(d) alloWing said embryo to develop to term. 
Furthermore, the invention provides a method of testing 
the ef?cacy of drugs in treating neurodegenerative disorders 
comprising administering said drug to a mouse according to 
the invention, and determining the behavioral effects and 
tissue changes of said drug on said mouse. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
carrying out the invention. As is readily recogniZed the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIGS. 1A—1D shoW isolation and expression of the K14 
NT-3 transgene in transgenic mice. 1(A) shoWs the NT-3 
DNA Was ligated into the BamH1 site of the K14-hGH 
cassette vector and puri?ed. 1(B) shoWs founder offspring 
Were screened and transgene copy estimated by ?lm densi 
tometry from slot blots on Which 2 pg of denatured tail DNA 
Was bound by baking to Nytran membrane and hybridiZed 
With a 32P-labeled probe to the NT-3 sequence. 1(C) shoWs 
transgene expression Was measured by Northern analysis of 
RNA isolated from shaved back skin. 1(D) shoWs in situ 
hybridiZation using a 35S-labeled antisense probe made 
against the NT-3 mRNA con?rmed K14-NT-3 transgene 
expression in basal keratinocytes of the epidermis (left 
panel, control tail skin; right panel, transgenic tail skin). 
FIGS. 2A—2F shoW histological and immunocytochemi 
cal analysis of transgenic skin. Flank skin from control (A) 
and transgenic (B) mice Was hematoxylin and eosin stained. 
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Note increased siZe of touch dome (bracketed area) and 
increased cellularity beneath touch dome in transgenic 
sample. Innervation to the skin and touch domes Was visu 
aliZed by immunolabeling tissue sections using anti-PGP9.5 
(Ultraclone) (FIGS. 2C, 2D) and anti-NF150 (Chemicon) 
(FIGS. 2E, 2F) antibodies. PGP9.5 immunoreactivity Was 
more extensive overall in transgenic skin (FIG. 2D) com 
pared to control (FIG. 2C), particularly in areas surrounding 
hair follicles. Touch domes of NT-3 mice (FIG. 2F) Were 
larger and appeared to have greater innervation density than 
control touch domes (FIG. 2E). 
FIGS. 3A—3B shoW transgene expression of NT-3 
increases the number of Merkel cells and cutaneous myeli 
nated nerves. Histogram 3(A) illustrates the number of MCs 
per touch dome unit shoWs increased numbers of MCs 
associated With the larger touch dome areas in the NT-3 
transgenic skin. 3(B) left side shoWs cross section of saphe 
nous nerve of control mouse; right side is nerve from an 
NT-3 transgenic. Axon counts of this cutaneous nerve shoW 
a 60% increase in the number of myelinated and unmyeli 
nated ?bers. 
FIG. 4 shoWs enhanced expression of NT-3 increases the 
number of trkc expressing sensory neurons. 
STATEMENT OF DEPOSIT 
The plasmids used to transform the mice of the present 
invention have been deposited under the terms of the Budap 
est Treaty With the American Type Culture Collection, 
12301 ParklaWn Dr. Rockville, Md. 20852. The K14 NT-3 
hGH plasmid in E. coli has ATCC Accession No. 69889 and 
Was received Aug. 16, 1995. 
During the pendency of this application, access to the 
deposit Will be forWarded to one determined by the Com 
missioner to be entitled thereto; (b) all restrictions imposed 
by the depositor on the availability to the public of the 
deposited material Will be irrevocably removed upon the 
granting of the patent, (c) the deposit Will be maintained for 
a period of at least thirty years or at least ?ve years after the 
most recent request for the furnishings of a sample of the 
deposited material, (d) the deposit Will be replaced should it 
become necessary due to inviability, contamination or loss 
of capability to function in the manner described in the 
speci?cation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
To examine target-derived effects of neurotrophin-3 (NT 
3), transgenic mice Were isolated that overexpress NT-3 in 
the epidermis. Experiments that examine the neuroanatomi 
cal and neurochemical changes induced by NT-3 expression 
in skin are conducted. Neurons of the trigeminal, superior 
cervical, and dorsal root ganglia are examined. Behavioral 
testing is initiated to determine Whether alteration in sensory 
perception is induced by the increased neuronal innervation. 
Transplantation studies examine the usefulness of the trans 
genic skin in supplying NT-3 to neuronal lesion sites. 
It Was discovered that the production of NT-3 in trans 
genic mice alters the peripheral nervous system by rescuing 
NT-3 responsive neurons from a programmed cell death that 
normally occurs in development. This is evidenced by an 
increase in the number of trk C receptor expressing sensory 
neurons. 
In addition, K14-NT-3 mice have larger Merkel cell 
(touch dome) sensory units in the skin than controls. These 
mice can be used in conjunction With K14-NGF and K14 
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BDNF transgenic mice to examine the role and possible use 
of neurotrophic compounds in controlling the development 
and function of the nervous system. 
Neurotrophins are groWth factors that have profound 
effects on the development and function of the mammalian 
nervous system. Transgenic mice Were isolated that express 
increased levels of NT-3 in the epidermis and other strati?ed, 
keratiniZed epithelium. The transgene DNA construct 
injected into mouse embryos contains the human K14 kera 
tin promoter and enhancer region linked to the coding 
sequences of the mouse NT-3 gene (FIG. 1). To increase 
expression of the transgene, a region from the human groWth 
hormone gene Was added at the 3‘ end of the construct. 
Eleven founder mice Were isolated; three lines Were devel 
oped for further use. 
The results support the neurotrophic hypothesis and spe 
ci?cally demonstrate that the skin, by regulating the timing 
and amount of neurotrophin expression independent of 
innervation plays a central role in the development of the 
peripheral nervous system. 
Elevated levels of NT-3 in the mice of the invention Were 
found to increase the siZe of touch dome units, the number 
of Merkel cells (MC) per unit, and their level of neuronal 
innervation. In addition, the number of myelinated and 
unmyelinated axons in cutaneous nerves Was increased 
approximately 60% While the number of trkC expressing 
neurons in the trigeminal ganglia doubled. 
Previous studies of transgenic mice that overexpress NGF 
in the skin shoWed a dramatic increase in innervation 
density, an increase in the number of trkA expressing 
neurons, and an overall hypertrophy of the peripheral ner 
vous system (1, 2). Because skin also synthesiZes the 
neurotrophins NT-3, BDNF, and NT-4 during critical periods 
of sensory neuron development (3, 4, 5), We developed 
additional lines of neurotrophin expressing mice. 
The transgenic mice of the invention overexpress NT-3 in 
the epidermis. The expression of NT-3 by the skin suggests 
that it may, like NGF, support distinct subsets of cutaneous 
sensory neurons and thereby in?uence development of 
innervation density and sensory responsiveness (1, 6, 7, 8). 
NT-3 gene expression is detectable in developing skin at 
embryonic day 9.5 (E9.5), peaks at E13, and then declines 
to loWer adult levels To increase levels of target-derived 
NT-3, transgenic mice Were isolated that overexpress NT-3 
in basal keratinocytes of the epidermis using promoter and 
enhancer sequences of the human keratin K14 gene (1, 10) 
(FIG. 1a). Expression of K14 in developing epidermis is 
initiated by approximately day 14 and continues in the adult. 
The onset of transgene expression, therefore, overlaps With 
the normal decline of NT-3 expression in the skin. HeteroZy 
gote transgenic offspring from K14-NT-3 founder mice 
(FIG. 1B) appeared normal. They Were characteriZed for 
transgene mRNA expression using Northern analysis of 
RNA isolated from back skin (FIG. 1C) and in situ hybrid 
iZation analysis of tail skin (FIG. 1D). TWo lines (696-2 and 
694-2) that expressed the highest levels of the K14-NT-3 
transcript Were used for this study. 
Histological examination of transgenic skin shoWed a 
remarkable increase in the siZe of touch domes (FIG. 2A, B), 
mechanoreceptor units innervated by large diameter, sloWly 
adapting type I (SAI) sensory neurons (11). Touch domes of 
transgenic mice (FIG. 2B) Were nearly doubled in siZe 
compared to controls (FIG. 2A). In dermis beneath touch 
domes an increased cellularity Was consistently observed 
and appears to represent SchWann cells associated With the 
innervating ?bers. An increased labeling density in this 
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region With an antibody that recogniZes a galactocere 
broside component of myelin protein expressed in SchWann 
cells (01 antibody) is noted. 
To examine the nature of innervation to touch dome units, 
sections of control and transgenic skin Were immunolabeled 
using an antibody against protein PGP 9.5 (FIG. 2C, D), 
Which recogniZes all neuronal ?ber types, and an antibody 
against neuro?lament 150 (NF 150; FIG. 2E, 2F), a protein 
primarily localiZed to myelinated axons. An increase in the 
density of innervation to the skin and touch dome units of 
the transgenic mice (FIG. 2C, 2D) appeared in large part 
attributable to increased projection of afferents to hair 
follicles, particularly in regions Where circular endings Were 
located. Given the physiologically measured decrease in 
D-hair units in skin of NT-3 (+/—) mutant mice (12), this 
increase shoWs that these circular endings may represent the 
anatomical substrate of the D-hair unit. The clearly larger 
touch dome units of transgenics Were also innervated by an 
increased number of immunoreactive ?bers (FIG. 2F) com 
pared to controls (FIG. 2E), suggesting that the transgenic 
touch domes are enhanced functionally as Well. 
SAI afferents innervating touch domes terminate on spe 
cialiZed neuroendocrine cells knoWn as Merkel cells (MCs). 
MCs are located at the epidermal-dermal junction and are 
thought to act as transducers of mechanical deformation 
(13). To determine Whether MC numbers Were increased in 
conjunction With the increase in touch dome area and 
innervation, control and transgenic mice Were injected With 
quinacrine ?uorescent dye, a compound selectively concen 
trated in neuroendocrine cell types (14). Counts of quina 
crine labeled control and transgenic skin shoWed a statisti 
cally signi?cant (p<0.001) increase in the number of MCs 
per touch dome in the NT-3 transgenics (FIG. 3A). 
Gene knockout and cell culture studies have shoWn NT-3 
supports the survival of myelinated sensory neurons of large 
axonal caliber (15, 16). To examine Whether overexpression 
of NT-3 affected cutaneous myelinated nerves, We measured 
the number of myelinated ?bers in control and transgenic 
mice by counting cross-sectional pro?les of the saphenous 
cutaneous nerve (ie. 3B). Axon counts from control 
(521168 s.e.m.) and transgenic 8391118 s.e.m.) mice 
shoWed transgenic nerves to have an approximate 60% 
increase in the number of myelinated ?bers ((p<0.001) 
compared to controls). This increase in axon count Was 
re?ected by the near doubling of the transgenic saphenous 
nerve cross-sectional area (FIG. 3B, right side) compared to 
the control nerve (FIG. 3B, left side) (34,016 units pmz 
compared to 17,196 pmz, p<0.001). Subsequent counting of 
unmyelinated axons shoWed there number to also be 
increased by 60%. 
The biological effects of neurotrophins are primarily 
mediated through the trk family of tyrosine protein kinases 
(17, 18, 19). TrkA preferentially binds NGF, trkB binds 
BDNF and NT-4, and trkC binds NT-3. Approximately 10% 
of dorsal root ganglia (DRG) sensory neurons express the 
trkC receptor, 10% express the trkB receptor, Whereas 40% 
express trkA (20, 21, 22, 23). 
Target production of neurotrophins affects neuron sur 
vival and differentiation via a trk receptor mediated uptake 
process that facilitates internaliZation and retrograde trans 
port to the soma (24). Abundant evidence supports this 
mechanism for the prototypical neurotrophin NGF and its 
high af?nity receptor trkA. Mice lacking a functional NGF 
gene lack trkA expressing neurons (8), Whereas mice that 
overexpress NGF have an increased number of trkA express 
ing neurons 
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To examine Whether increased expression of NT-3 acted 
to increase the number of sensory neurons that expressed 
trkC, in situ hybridization Was carried out using a radiola 
beled probe to the trkC receptor mRNA (25). Trigeminal 
ganglia from the 694-2 and 696-2 transgenic lines had an 
approximate tWo-fold increase in the number of trkC 
expressing neurons compared to control ganglia (Table 1). 
Interestingly, a plot of these values versus animal age (FIG. 
4) revealed that, for both control and transgenic mice, the 
number of the trkC positive neurons accumulated With age, 
stabiliZing by approximately three Weeks. This increase in 
trkC neurons may re?ect a maturation and/or re?nement of 
the sensory system during the early Weeks of development 
and demonstrates the plasticity inherent in the peripheral 
sensory system. 
Studies of NT-3 and trkC gene knockout mice shoWed a 
depletion of proprioceptive 1A afferents as Well as the 
muscle spindle sensory end organs they innervate (15, 16, 
26). The disappearance of proprioceptive neurons cannot, 
hoWever, account for the overall 50% loss of sensory neu 
rons in the DRG of NT-3 (—/—) animals and suggests other 
sensory neurons are dependent on NT-3 for their develop 
ment and maintenance. 
The present studies identify cutaneous touch dome com 
plexes and their associated MCs as another sensory end 
organ responsive to NT-3 and, by supposition, innervated by 
trkC receptor expressing neurons. This observation is sup 
ported by the additional innervation to touch dome units, the 
increase in MCs, and the increase in trkC expressing neurons 
in the sensory ganglia (FIG. 4). 
The enlargement of touch domes and number of MCs may 
result from the enhanced innervation by SA1 afferents 
generated by the increased level of NT-3. In support of this 
mechanism, studies by Nurse et al., (27) shoWed that den 
ervation of backskin of rats led to a decline in the number of 
MCs, i.e., the sensory nerve supply Was required for MC 
maintenance. In addition, MCs are depleted in NT-3 (+/—) 
mice Which lack SA1 type ?bers (12). 
In the present model an overabundance of appropriate 
SA1?ber types appear available to contact MCs and, 
interestingly, this overabundance enhances the development 
of the end organ. Effects of the epidermally expressed NT-3 
on the cells comprising the touch dome is another possible 
factor in touch dome development, perhaps acting in a 
synergistic manner With the afferent innervation. 
Table 1. Number of TrkC receptor expressing neurons in 
the trigeminal ganglion of control and K14-NT-3 transgenic 
mice. Positive cells Were counted in every tenth section of 
serial sectioned ganglia. Transgenic and control ganglia 
Were hybridiZed together and therefore exposed to the same 
conditions. 
TABLE 1 
Age TrkC labeled neurons 
Sample (Weeks) (avg) 
Transgenic line 696-2 5 (n = 2) 62 
7 (n = 1) 259 
9 (n = 2) 283 
26 (n = 1) 327 
Transgenic line 694-2 6 (n = 4) 113 
23 (n = 2) 342 
44 (n = 1) 294 
Controls 63 (n = 2) 417 
5 (n = 2) 37 
7 (n = 2) 90 
9 (n = 1) 116 
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TABLE 1-continued 
Age TrkC labeled neurons 
Sample (Weeks) (avg) 
23 (n = 1) 189 
26 (n = 1) 15s 
44 (n = 2) 156 
63 (n = 1) 214 
To correct for variation in neuron siZe, recursive transla 
tion analysis Was performed on labeled neuron cell counts. 
The perimeter of labeled neuronal pro?les Were draWn 
by camera lucida and the cross sectional area (A) of each 
pro?le calculated from a digitiZed image of the draWing. The 
radius (r) of each pro?le Was approximated using r=square 
root of The frequency histogram of the pro?le radii 
Was transformed to an estimate of the true frequency histo 
gram of neuronal radii With a computer program developed 
by Rose and Rohrlich (30). Summing the frequencies in all 
bins of the resulting histogram gives an estimate of cell 
number in one section of a ganglion. The recursive transla 
tion method Was repeated on equally spaced 20 pm serial 
sections (for example, on every n”1 section) throughout the 
entire ganglion. Summing the number of cells across all of 
the sampled sections and multiplying the total by n gives an 
unbiased estimate of the true number of labeled cells. n 
equals the number of mice used per age group. 
DETAILED DESCRIPTION OF DRAWINGS 
FIG. 1 shoWs isolation and expression of the K14-NT-3 
transgene in transgenic mice. Mouse NT-3 cDNA Was 
cloned by PCR ampli?cation of DNA isolated from tail 
using primers (5‘CCAGCG 
GGATCCGTGKFGTCCATCTTGTTTTATGTG 3’ (SEQ ID 
N011) and 5’CGGTAC 
GGATCCGATGCCAATTCATGTTCTTCCG 3‘ (SEQ ID 
NO:2)) that ampli?ed the DNA sequence encoding amino 
acids —140 to +124 according to the numbering of Yanco 
poulos et al., (28). This region contains the putative signal 
peptide (—140 to —1), the mature peptide (+1 to +119), and 
the NT-3 stop codon (+120). To facilitate cloning, primers 
contained a BamH1 recognition sequence (underlined in 
sequence). DNA sequencing shoWed a nucleotide change in 
the cloned sequence that resulted in a conservative amino 
acid change (ala-val) at amino acid residue [—9]. 1(A) 
shoWs the NT-3 DNA Was ligated into the BamH1 site of the 
K14-hGH cassette vector (10) and puri?ed as described in 
(1). The K14-NT-3 sequence Was microinjected into pronu 
clei of B6><C3 F1 hybrid mouse embryos and implanted into 
pseudopregnant females using standard procedures (29). 
Four founder mice (696-2, 694-2, 709-9, and 662-8) Were 
identi?ed by Southern hybridiZation using a random primed 
32P-dCTP labeled probe made to the full length NT-3 cDNA. 
1(B) shoWs founder offspring Were screened and transgene 
copy estimated by ?lm densitometry from slot blots on 
Which 2 pg of denatured tail DNA Was bound by baking to 
Nytran membrane and hybridiZed With a 32p-labeled probe 
to the NT-3 sequence. Copy number estimates Were 8 (line 
696-2), 2 (line 694-2), 5 (line 709-9), and 3 (line 62-8). 
Because of poor reproductive yields of homoZygous mice, 
experimental analyses Were restricted to hemiZygous trans 
genics. 1(C) shoWs transgene expression Was measured by 
Northern analysis of RNA isolated from shaved back skin. 
RNAWas puri?ed using TriZol reagent (Gibco-BRL) accord 
ing to the manufacturers protocol. 10 pg of RNA Was 
resolved on a 1.2% agarose formaldehyde denaturing gel, 
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transferred to Nytran membrane, baked at 80° C., and 
hybridized at 65° C. in the presence of 50% formamide to a 
32P-CTP labeled riboprobe made to the full length NT-3 
sequence. Membranes Were hybridized overnight, Washed, 
and exposed to X-ray ?lm. Lane nt, nontransgenic RNA; 
lane 2, 662-8 RNA; land 3, 709-9 RNA; land 3, 694-2 RNA, 
and land 4, 696-2 RNA. 1(D) shoWs In Situ hybridization 
using a 35S-labeled antisense probe made against the NT-3 
mRNA con?rmed K14-NT-3 transgene expression in basal 
keratinocytes of the epidermis (left panel, control tail skin; 
right panel, transgenic tail skin). Conditions of probe hybrid 
ization Were as described in 
FIG. 2 shoWs histological and immunocytochemical 
analysis of transgenic skin. Flank skin from control (A) and 
transgenic (B) mice Was hematoxylin and eosin stained. 
Note increased size of touch dome (bracketed area) and 
increased cellularity beneath touch dome in transgenic 
sample. Innervation to the skin and touch domes Was visu 
alized by immunolabeling tissue sections using anti-PGP9.5 
(Ultraclone) (FIG. 2C, 2D) and anti-NF150 (Chemicon) 
(FIG. 2E, 2F) antibodies. PGP9.5 immunoreactivity Was 
more extensive overall in transgenic skin (FIG. 2D) com 
pared to control (FIG. 2C), particularly in areas surrounding 
hair follicles. 
Touch domes of NT-3 mice (FIG. 2F) Were larger and 
appeared to have greater innervation density than control 
touch domes (FIG. 2E). Immunolabeling Was done on 30 pm 
thick ?oating sections that Were blocked in 5% normal goad 
serum (NGS), 2% bovine serum albumin (SA), and 0.25% 
triton X-100 made in tris buffered saline for 1 h, exposed 
overnight at room temperature to diluted antibodies (anti 
PGP 9.5, 1:500 dilution of biotinylated goat anti-rabbit 
secondary for 1 h folloWed by a strepavidin complex incu 
bation (Vector Labs)). Binding Was visualized using a nickel 
cobalt enhanced diaminobenzidine reaction. Scale bars A—d, 
50 pm; E—F, 100 pm. 
FIG. 3 shoWs transgene expression of NT-3 increases the 
number of Merkel cells and cutaneous myelinated nerves. 
Histogram 3(A) illustrating the number of MCs per touch 
dome unit shoWs increased numbers of MCs associated With 
the larger touch dome areas in the NT-3 transgenic skin. 
Numbers Were determined for 3 transgenic and 3 controls by 
counting quinacrine hydrochloride labeled cells on full 
thickness skin sections using a microscope equipped With 
FITC ?uorescent optics (14). Back skin of adult mice Was 
depilated and 24 h later mice Were injected intraperitoneally 
(15 mg/kg) With quinacrine solution made in phosphate 
buffered saline. 20 h later mice Were deeply anesthetized and 
back skin removed and analyzed. 3(B) shoWs on the left side 
a cross section of saphenous nerve of control mouse; right 
side is nerve from an NT-3 transgenic. Saphenous nerves of 
transgenics Were nearly double in size compared to control 
nerves and had a 40% increase in the number of myelinated 
axons. Nerve samples Were collected from transgenic (n=3) 
and control (n=3) mice deeply anesthetized With Avertin and 
perfused intracardially With a solution of 2% paraformalde 
hyde and 2% glutaraldehyde made in phosphate buffer. 
Tissues Were ?xed overnight, embedded in epon, thin 
sectioned, stained With toluidine blue, and myelinated pro 
?les counted With the aid of a computer. Nerve counts and 
MC counts Were analyzed from the same mice. 
FIG. 4 shoWs enhanced expression of NT-3 increases the 
number of trkC expressing sensory neurons. To identify trkC 
neurons in trigeminal ganglia in situ hybridization Was 
performed using a 35S-labeled antisense probe made against 
rat trkC mRNA (25). Values at timepoints listed in Table 1 
Were plotted against age and shoW an overall increase of 
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trkC neurons for both transgenic lines compared to controls 
and reveal a signi?cant positive correlation betWeen the 
number of trkC neurons and age for both transgenic (line 
694-2, r=0.626 p<0.05) and control (r=0.802; p<0.005) 
mice. Control (-“box”-); line 696-2 (—“dark circle”-); line 
694-2 (-o). 
TABLE 2 
Number of trk C 
Mouse Number Phenotype Labeled neurons 
711-2 Nontransgenic 272 
696-2F1-25 Nontransgenic 292 Average value 
696-2NT14 Nontransgenic 136 for nontransgenic 
696-2NT17 Nontransgenic 208 mice = 227 
696-2F2-6 Transgenic 758 
694-2 Transgenic 645 Average value 
696-2F2-30 Transgenic 515 for transgenic 
696-2F2-27 Transgenic 649 mice = 642 
EXAMPLE 1 
Construction of K14-NT-3 transgene and introduction 
into mice. Transgenic mice that overexpress NT-3 in the skin 
Were generated by linking a PCR cloned NT-3 cDNA 
doWnstream of 2 Kbp of the human D14 keratin promoter 
and enhancer sequence. NT-3 cDNA Was cloned by PCR 
ampli?cation of DNA isolated from tail using primers 
( 5 ‘ C C A G C G 
GGATCCGTGKFGTCCATCTTGTTTTATGTG 3‘ (SEQ ID 
NO:1) and 5‘CGGTAC 
GGATCCGATGCCAATTCATGTTCTTCCG 3‘ (SEQ ID 
NO:2)) that ampli?ed the DNA sequence encoding amino 
acids —140 to +124 according to the numbering of Yanco 
poulos et al. This region contains the putative signal peptide 
(—140 to —1), the mature peptide (+1 to +119), and the NT-3 
stop codon (+120). To facilitate cloning primers Were gen 
erated to contain a BamH1 recognition sequence (underlined 
in primer sequence). Sequencing of the cloned NT-3 shoWed 
a nucleotide change that resulted in a conservative amino 
acid change (alaQval) in the signal peptide region at amino 
acid residue [—9]. To construct the K14-NT-3-hGH trans 
gene the NT-3 cDNA Was ligated into the BamH1 site of the 
K14-hGH cassette vector (Vassar and Fuchs, 1991, supra). 
Dr. Elaine Fuchs (University of Chicago) provided the 
K14-hGH plasmid. 
K14-hGH contains 2.1 kbp of 5‘ upstream sequence of the 
human K14 keratin gene and a 1.8 kbp intron containing 
sequence from the human groWth hormone (hGH) gene. The 
hGH sequence serves to upregulate expression of the trans 
gene and provides a polyadenylation signal. (See Sandgren, 
E.P., Luetteke, N.C., Palmiter, R. D., Brinster, R. L. & Lee, 
D. C. (1990), “Overexpression of TGF alpha in transgenic 
mice: Induction of epithelial hyperplasia, pancreatic 
metaplasia, and carcinoma of the breast,” (Cell 61, 
1121—1135). 
The 5-kbp EcoR1 k14-NT-3-hGH fragment (FIG. 1a) Was 
isolated on 0.8% Seaplaque agarose gel (FMC Corporation), 
extracted from the gel using glassmilk puri?cation 
(Geneclean Bio 101), and run through a NACS column 
(Bethesda Research Laboratories). 
The plasmid used to transfect mouse cells according to the 
present invention (K14-NT-3)-hGH has been deposited in E. 
coli With the American Type Culture Collection under the 
terms of the Budapest Treaty and is available as Accession 
No. [69889]. 
DNA Was ethanol precipitated, resuspended in phosphate 
buffered saline at a concentration of 5 pig/ml, and injected 
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into fertilized B6><C3 F1 hybrid mouse (Harlan Laboratory 
Supplies) embryos. Injections and implantations Were car 
ried out using standard procedures. (See Hogan, B., 
Costantini, F. & Lacy, E. (1986). Manipulating the Mouse 
Embryo: A Laboratory Manual (Cold Spring Harbor Press, 
Cold Spring Harbor, 
Mice Were screened for the transgene using Southern 
hybridization analysis on DNA extracted from tail and by 
slot blot hybridiZation. For Southern hybridiZations, 10 pg of 
DNA Was digested With BamH1, separated on an 0.7% 
agarose gel, transferred to nitrocellulose by blotting and 
probed With a random primed 32P-dCTP (NeW England 
Nuclear) labeled probe made to the full length NT-3 cDNA. 
EXAMPLE 2 
Analysis of mRNA expression by Northern hybridiZation. 
Northern analysis Was performed on RNA that Was isolated 
from various tissues using guanidium thiocyanate/phenol/ 
chloroform extraction. (See ChomcZynski, P. & Sacchi, N. 
(1987), “Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction,” 
Analyt. Biochem. 162, 156—159). 
Ten micrograms of total RNA Was resolved on a 1.2% 
agarose formaldehyde denaturing gel, transferred to Nytran 
membrane (Schleicher and Schuell) by blotting, baked 2 h at 
80° C., and then hybridiZed to a 32P-dCTP labeled riboprobe 
made to the full length NT-3 cDNA. 
EXAMPLE 3 
In situ hybridiZation. 35S-labelled cRNA probes Were 
generated by adding 1 pg of lineariZed to 2.5 mM each ATP, 
CTP, GTP, 15 mM [35S]UTP (NeW England Nuclear) and 
either T7 or T3 polymerase (Stratagene) to generate anti 
sense and sense probes, respectively. Incubation Was for 60 
min at 40° C. in transcription buffer containing 50 mM 
MgCl2, 20 mM spermidine, 20 mM Tris (pH 7.4) and 10 mM 
DTT. The solution Was phenolzchloroform extracted and 
precipitated With ammonium acetate and 2.5 volumes of 
ethanol in the presence of 25 pg carrier tRNA. 
For in situ hybridiZation, tail skin Was dissected, imme 
diately froZen on dry ice, cryostated at 20 pm, mounted onto 
Glass plus slides and stored at —80° C. until hybridiZed. To 
hybridiZe, slides Were brought to room temperature, ?xed 
for 10 min in 4% paraformaldehyde, Washed in diethyl 
pyrocarbonate (DEPC)-treated phosphate buffer, transferred 
to 0.25% acetic anhydride in 0.1M TEA (pH 8/0) for 10 min 
at room temperature, dehydrated through a graded series of 
alcohols and defatted in chloroform. Sections Were hybrid 
iZed for 12—24 hr at 60° C. in a hybridiZation solution 
consisting of 1><107 cpm/ml of 35S-labeled cRNA probe, 
50% formamide, 1>< Denhardt’s solution, 200 mM Tris (pH 
7.5), 10% dextran sulfate, 0.3 pig/ml salmon sperm DNA, 
0.15 mg/ml tRNA, and 40 mM DTT. Slides Were Washed in 
4><SSC (1><SSC=0.15M NaCl, 0.015M sodium citrate, pH 
7.0), incubated in 20 mg/ml ribonuclease A (Sigma) dis 
solved in 10 mM Tris-saline, and then Washed through 
descending concentrations of SSC. The ?nal Wash Was With 
0.1><SSC at 37° C. for 1 hour. 
Sections Were air-dried and placed in X-ray cassettes With 
Hyper?lm [3-Max X-ray ?lm (Amersham). Films Were 
exposed for 3—7 days and developed in Kodak D-19. 
Selected slides Were dipped in Kodak NTB-2 liquid 
emulsion, air-dried and exposed to ?lm. Emulsion dipped 
slides Were developed in D19, ?xed in Kodak rapid ?xer, 
counterstained With hematoxylin/eosin or cresyl violet and 
coverslipped in Permount. 
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Skin sections from transgenic mice and non-transgenic 
siblings Were processed in parallel. Controls for probe 
speci?city included hybridiZation using a sense cRNAprobe 
and pretreatment of tissue With RNase. Both of these con 
ditions resulted in the absence of hybridiZation. 
EXAMPLE 4 
Immunohistochemistry. Skin from mice typically 
betWeen 4—6 months of age Was analyZed. Mice Were deeply 
anesthetiZed With Avertin and transcardially perfused With 
4% paraformaldehyde in phosphate buffer. Tissue Was 
removed and immersion ?xed for at least 4 h, placed in 25% 
sucrose overnight, embedded in gelatin and cut at 40 pm 
thickness on a sliding microtome. Sections Were blocked for 
1 h in 5% normal goat serum (NGS), 2% bovine serum 
albumin (BSA), and 0.25% triton X-100 made in Tris 
buffered saline (100 mM Tris; 5 mM NaCl; pH 7.4) for 1 h, 
exposed overnight at room temperature to a primary anti 
body (anti-PGP 9.5, 15000; anti-NF150, 1:3000; dilutions 
made in 5% NGS and 0.25% triton), Washed, and incubated 
in a 1:500 dilution of biotinylated goat anti-rabbit secondary 
for 1 h folloWed by a strep-avidin complex incubation 
(Vector Labs). Antibody binding Was visualiZed using a 
nickel cobalt enhanced diaminobenZidine reaction. 
Merkel cell and touch dome counting. To identify touch 
domes and Merkel cells associated With touch domes located 
on ?ank skin of adult mice skin Was depilated and 24 h later 
mice Were injected intraperitoneally With quinacrine 
(Sigma) (15 mg/kg; made in phosphate buffered saline), a 
?uorescent dye that concentrates in neuroendocrine cell 
types (14). 12—20 h folloWing injection mice Were deeply 
anesthetiZed and killed by cervical dislocation and ?ank skin 
removed. The skin Was trimmed of connective tissue, 
mounted on a glass slike With a coverslip using glycerol, and 
Merkel cells associated With touch dome units counted using 
FITC ?uorescence optics. The number of touch domes per 
cm2 of ?ank skin Was determined in a similar manner. 
EXAMPLE 5 
NT-3 may be used in the diagnosis and/or treatment of 
neurologic disorders, including, but not limited to, periph 
eral neuropathies, such as diabetic neuropathies, toxic and 
nutritional neuropathies, hereditary neuropathies, and AIDS 
related neuropathies, as Well as degenerative diseases such 
as amyotrophic lateral sclerosis It has been shoWn 
that NT-3 supports the survival of dopaminergic neurons. 
Accordingly, in a preferred embodiment, NT-3 may be used 
for the diagnosis of Parkinson’s disease. Because NT-3 has 
been observed to exhibit a spectrum of activity different 
from brain derived neurotrophic groWth factor (BDNGF) 
and nerve groWth factor (NGF), NT-3 provides neW and 
valuable options for inducing the regroWth and repair of the 
central nervous system. 
The transgenic mice in accordance With the present 
invention, thus provide an in vivo model for testing drug 
interactions With neurons Which are stimulated by NT-3. The 
K14-NT-3 mice are valuable to researchers that study the 
role of NT-3 in development and function of the adult 
nervous system. An area of intense study is the role of NT-3 
in neurodegenerative disorders of the CNS and PNS. In 
addition, NT-3 has been shoWn to have antinociceptive 
effects (i.e., increase in tail-?ick and hot plate response 
latency). Academic researchers as Well as biotechnology 
companies are involved in such studies and Would have 
interest in these mice as model systems in basic research 
studies as Well as for applied studies such as drug testing. 
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To test the reaction and/or of drugs in treating neurode 
generative disorders, a drug candidate is administered to a 
mouse according to the invention. The behavioral effects and 
tissue changes of the mouse are determined upon adminis 
tration of the drug. 
References 
1. K. M. Albers, D. E. Wright, B. M. Davis, J. Neuroscience 
14, 1422 (1994). 
2. T. P. Goodness, K. Albers, F. Davis, submitted. 
3. L. C. Schecterson and M. BothWell,Neuron 9, 449 (1992). 
4. A. M. Davies, A. Horton, L. E. Burton, J. Neurosci. 13, 
4961 (1993). 
5. U. Arumae, U. Pirvola, J. PalgiJ. Cell Biol. 122, 1053 
(1993). 
6. R. M. Lindsay and A. J. Harmar, Nature, 337, 362 (1988). 
7. R. W. Oppenheim, Ann.Rev. Neurosci. 14, 453 (1991). 
8. C. Crowley, S. D. Spencer, M. C. Nishimura, Cell 76, 
1001 (1994). 
9. V. L. Buchman and A. M. Davies, Development 118, 989 
(1993). 
10. R. Vassar and E. Fuchs, Genes and Develop. 5, 714 
(1991). 
11. F. Pasche, Y. Merot, P. CarrauXJ. Invest. Derm. 95, 247 
(1990). 
12. M. S. Airaksinen, M. KoltZenburg, G. R. LeWin, sub 
mitted. 
13. K.-M. Gottschaldt and C. Vahle-HinZ, Science 214, 183 
(1981). 
14. C. A. Nurse and J. Diamond, Neuroscience 11, 509 
(1984). 
15. P. Ernfors, K.-F. Lee, J. Kucera, Cell 77, 503 (1994). 
16. I. Farinas, K. R. Jones, C. Backus, Nature 369, 658 
(1994). 
17. S. O. Meakin and E. M. Shooter, Trends Neurosci.15, 
323 (1992). 
10 
15 
20 
25 
30 
16 
18. N. Y. Ip, T. N. Stitt, P. Tapley, Neuron 100, 137 (1993). 
19. V. M. K. Verge, J. P. Merlio, J. Grondin, J. Neurosci. 12, 
4011 (1992). 
20. M. Barbacid J. Neurosci. 25, 1386 (1994). 
21. P. Ernfors, C. M. Rosario, J .-P. Merlio, Mol. Brain 
Res.17, 217 (1993). 
22. X. Mu, I. Silos-Santiago, S. L. Carroll, J. Neurosci. 13, 
4029 (1993). 
23. D. E. Wright and W. D. Snider, J. Comp. Neurol. 351, 
329 (1995). 
24. R. Levi-Montalcini, Science 237, 1154 (1987). 
25. J. E. Dixon and D. McKinnon, Dev. Brain Res. 77, 177 
(1994). 
26. R. Klein, 1. Silos-Santiago, R. J. Smeyne, Nature, 368, 
249 (1994). 
27. C. A. Nurse, L. Macintyre, and J. Diamond, Neuro 
science 11, 521 (1984). 
28. G. D. Yancopoulos, P. C. Maisonpierre, N. Y. Ip, Cold 
Spring Harbor Symposia on Quantitative Biology 55, 371 
(1990). 
29. B. Hogan, F. Costantini, E. Lacy Manipulating the 
Mouse Embryo: A Laboratory Manual (Cold Spring Har 
bor Press, Cold Spring Harbor, NY, 1986). 
30. R. D. Rose and D. Rohrlich, J. Comp. Neurol. 263, 365 
(1987). 
The purpose of the above description and eXamples is to 
illustrate some embodiments of the present invention With 
out implying any limitation. It Will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention Without departing from the spirit or scope of the 
invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
SEQUENCE LISTING 
( 1 ) GENERAL INFORMATION: 
( i i i )NUMBER OF SEQUENCES: 2 
( 2 ) INFORMATION FOR SEQ ID NO:1: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 36 base pairs 
( B ) TYPE: nucleic acid 
( c ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i ) MOLECULE TYPE: DNA (genomic) 
( i i i ) HYPOTHETICAL: NO 
( i v )ANTI-SENSE: N0 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1: 
CCAGCGGGAT CCGTGATGTC CATCTTGTTT TATGTG 
( 2 ) INFORMATION FOR SEQ ID NO:2: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 34 base pairs 
( B ) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
36 
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-continued 
( i i )MOIECUIE TYPE: DNA (genomic) 
( i i i )HYPOTHETICAL:NO 
( i v )ANTI-SENSE: N0 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
CGGTACGGAT CCGATGCCAA TTCATGTTCT TCCG 34 
We claim: 
1. A transgenic mouse Whose somatic and germ cells 
contain and express an NT-3 transgene encoding mouse 
neurotrophic growth factor 3 (NT-3), Wherein as a result of 
said expression, the peripheral nervous system of said 
mouse exhibits the following characteristics: 
(a) NT-3 responsive neurons that are rescued from pro 
grammed cell death that normally occurs during the 
development of said mouse; 
(b) an increase in sensory neurons that express trk C 
receptor relative to a mouse that does not express said 
NT-3 transgene; and 
(c) larger Merkel cell sensory units in the skin of said 
mouse than in the skin of a mouse that does not express 
said NT-3 transgene; 
and further Wherein said NT-3 transgene comprises a mouse 
NT-3 gene operatively linked at its 5‘ end to a human K14 
keratin promoter and enhancer region and operatively linked 
at its 3‘ end to a contiguous 1.8 kbp region of the human 
groWth hormone gene, said region comprising (1) an intron 
15 
25 
30 
of the human groWth hormone gene, and (2) a polyadeny 
lation signal sequence. 
2. The mouse of claim 1, Wherein said mouse is fertile and 
capable of transmitting said NT-3 gene to its offspring. 
3. The mouse of claim 1, Wherein said NT-3 gene has been 
introduced into an ancestor of said mouse at an embryonic 
stage by microinjection. 
4. The mouse of claim 1, Wherein said human K14 keratin 
promoter and enhancer region is a 2.1 kbp sequence 5‘ 
upstream from the human K14 keratin gene. 
5. The mouse of claim 1, Wherein said NT-3 transgene is 
contained in a plasmid having American Type Culture 
Collection Accession No. 69889. 
6. A method of testing the effect of a drug on the mouse 
of claim 1, comprising administering said drug to said 
mouse, and thereafter determining any behavioral effects 
and tissue changes in said mouse. 
7. The method of claim 6, Wherein said drug is a candidate 
for treatment of a neurodegenerative disorder. 
* * * * * 
